BRAIN

High-Grade

NCCTG N0577   Screening consent   Consent   HIPAA    Protocol  (temporary closure 12/20/11)

Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

RTOG R0834   Screening Consent   Consent   HIPAA   Protocol    Fast Facts

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: the CATNON Intergroup Trial

NCCTG N057K   Consent   HIPAA    Protocol   (temporary closure 9/22/2011)

Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

Low-Grade

CTSU E3F05    Consent    HIPAA    Fast Facts    Protocol    

Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

RTOG R0539  Consent    HIPAA     Protocol    (Group 1 closure 9/29/10) (Group II closure 5/12/2011)

Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk  

Recurrent

NCCTG N0872  Consent   HIPAA   Protocol   (temporary closure 1/16/12)

Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Study 2)

Brain Mets

NCCTG N107C  Consent   HIPAA    Protocol   

A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

NCCTG N0574  Consent   HIPAA   Fast Facts    Protocol

Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases

RTOG R0933     Consent    HIPAA    Protocol

A Phase II Trial of Hippocampal Avoidance During Whole-Brain Radiotherapy for Brain Metastasis

BREAST

Breast - Other

NSABP DMP1    Consent   HIPAA   Protocol    Fast Facts

A Study to Evaluate Different Decision-making Approaches Used by Women Known to be at Increased Risk for Breast Cancer

CTSU SCUSF0806  Consent     HIPAA     Protocol     Schema

Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab

Breast DCIS

NSABP B43 Consent    Consent(pre-entry)    HIPAA    HIPAA(Pre-entry)    Protocol     Fast Facts   Treatment Calendar

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Breast - Node Negative

Breast -  Node Positive or Negative

CTSU E5103  Consent    HIPAA   Fast Facts    Protocol    Treatment Calendar (classical step 1)  Classical step 2       Dose-dense step 1   Dose-dense Step 2   AE Flowsheet   (Step 1 closure)

A Double-blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel and Bevacizumab or Placebo in Patients with Lymph Node Positive and High-risk Lymph Node Negative Breast Cancer

NSABP B-39   Consent    HIPAA  Fast Facts     Protocol  (Closed to specific patients)(QOL closed) Treatment Calendar

A Randomized Phase III Study of Conventional Whole Breast Irradiation versus Partial Breast Irradiation for Women with Stage 0, I or II Breast Cancer

SWOG S0800   Consent    HIPAA     Protocol  Treatment Calendar Arm1   Arm2   Arm3

A Randomized Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin and Cyclophosphamide plus Pegfilgrastim as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/NEU Negative Breast Cancer

NSABP B47    Consent     HIPAA   Fact Sheet   Protocol   

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High Risk Node-Negative HER2-low Invasive Breast Cancer

SWOG S1007   Consent-step 1       Consent-step2     HIPAA    Fast Facts   Protocol  

A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and HER2 Negative Breast Cancer with Recurrence Score of 25 or Less

RTOG R1005   Consent    HIPAA    Protocol 

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer

Her2+

CTSU SCUSF0806  Consent     HIPAA     Protocol     Schema

Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab

Neo Adjuvant

CTSU C40603     Consent     HIPAA    Fact Sheet   Protocol    (temporary closure 11/10/11)

Randomized Phase II 2X2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-negative Resectable Breast Cancer

CTSU C40601  Consent   HIPPA    Fast Facts    Protocol    

Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of Her2-Positive Primary Breast Cancer

Adjuvant--Hormonal

Breast - Inflammatory

SWOG S0800   Consent    HIPAA     Protocol  (temporary partial closure-pre-menopausal women 1/25/12)

A Randomized Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin and Cyclophosphamide plus Pegfilgrastim as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/NEU Negative Breast Cancer

Breast - Regional Relapse

RTOG R1014   Consent   HIPAA    Protocol  

A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation for Local Recurrence of Breast Carcinoma

Breast - Metastatic

SWOG S0500    Consent    HIPAA   Fast Facts     Protocol     Treatment Calendar

A Randomized Phase II Trial to Test the Strategy of Changing Therapy vs Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment

NCCTG N0733      Consent   HIPAA  Schema  Protocol  Treatment Calendar Arm A     Arm B   

Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane

NCCTG N0937   Consent    HIPAA   Protocol   

Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer

CTSU E3108   Consent   HIPAA   Schema   Protocol 

A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen

CTSU E2108    Consent    HIPAA   Fast Facts   Protocol    

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

GASTROINTESTINAL

Colon - Rectal

Prevention Stage 0 - III Colon

SWOG S0820   Consent    HIPAA     Protocol  Calendar     (Hold for drug supply)

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

NSABP P-5   Consent    HIPAA   Protocol   Fact Sheet     Treatment Calendar

Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Stage II Colon

Stage III Colon

CTSU C80702  Consent    HIPAA  Fast Facts    Protocol   Treatment Calendar Arm A/B                                           Treatment Calendar ArmC/D    AE Flowsheet

A Phase III Trial of 6 vs 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer                                                                                                            Also SEE N08CB for Neuropathy prevention

Metastatic Colon

CTSU CALGB 80405     Consent   HIPAA    Fast Facts     Protocol   ( QOL closed)(closure Arm C)                            Treatment Calendar Arm A     Treatment Calendar Arm B

Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Small Bowel

NCCTG N0543  Consent    HIPAA     Protocol    Treatment Calendar Arm A    Arm B    Arm C

A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adencarcinoma

Metastatic 2nd Line

Rectal

Stomach

SWOG S1005     Consent     HIPAA      Protocol  

A Phase II Study of MK-2206 as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer

Esophageal

RTOG R0436    Consent   HIPAA  Fast Facts  Protocol   Treatment Calendar Arm 1  Arm 2 

A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery

NCCTG N0849    Consent    HIPAA     Protocol   

Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Gastric Cardia

RTOG R1010  Consent   HIPAA  Fast Facts   Protocol  

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Pancreas

RTOG R0848   Consent     HIPAA   Fast Facts   Protocol                                                                                                    Treatment Calendar Arm 1 Arm 2  Arm 3(1)   Arm 3(2)  Arm 4(1)  Arm 4(2)

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

CTSU C80701   Consent   HIPAA   Schema   Protocol  

Randomized Phase II Study of Everolimus Alone vs Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

Liver

CTSU E1208   Consent     HIPAA    Fast Facts    Protocol   

A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion

Gallbladder

Stromal

Carcinoid

SWOG S0518  Consent     HIPAA    Fast Facts   Protocol     Treatment Calendar Arm 1   Arm 2                          (temporary partial closure-pre-menopausal women 1/25/12)

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Cholangiocarcinoma

SWOG S0809    Consent     HIPAA       Protocol   Treatment calendar (permanent closure Stratum R0 12/15/11)

A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)

GENITOURINARY

RTOG R0831   Consent    QOL Consent    HIPAA    Protocol   Schema

A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer

Prostate-Local

CTSU CALGB 90203    Consent    HIPAA   Fast Facts  Protocol

Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

RTOG R0622     Consent     HIPAA     Protocol   

A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy

RTOG R0815    Consent   HIPAA  Fast Facts  Protocol   

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

SWOG S1014  Consent     HIPAA    Protocol   

Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II

Prostate-Recurrent

RTOG R0534  Consent     HIPAA   Fast Facts    Protocol  

A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy

Prostate-Metastatic

SWOG S0925     Consent    HIPAA     Protocol   

A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer

CTSU E3805    Consent    HIPPA    Fast Facts     Protocol    Treatment Calendar Arm A     Arm B

CHAARTED:  Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

CTSU CALGB 90202    Consent    HIPAA   Fast Facts     Protocol    Treatment Calendar-Blinded     Open Label

A Randomized, Double-blind, Placebo-controlled Phase III Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal-related Events in Men with Prostate Cancer Metastatic to Bone

Bladder/Urothelium

RTOG R0524      Consent    HIPAA   Schema  Protocol (temporary closure 10/25/11)

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Tranurethral Surgery for Non-Cystectomy Candidates with Muscle Invasive Bladder Cancer

SWOG S0337     Consent    HIPAA      Protocol 

A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer

    Germ Cell Malignancies

none

   Renal

CTSU C90601   Consent    HIPAA  Fast Facts  Protocol    Treatment Calendar

Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma

CTSU C90802    Consent   HIPAA  Fast Facts  Protocol 

Randomized Phase III Trial Comparing Everolimus Plus Placebo vs Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors

SWOG S0931   Consent   HIPAA    Protocol  Calendar

"EVEREST:  EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study

GYNECOLOGIC

      Ovarian

CTSU G0262   Consent    HIPAA   Schema   Protocol   

A Randomized Phase III Trial of Every 3-Weeks Paclitaxel vs Dose Dense Weekly Paclitacel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

CTSU G0241   Consent   HIPAA   Fast Facts    Protocol    (temporary partial closure-pre-menopausal women 1/25/12)

A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First-Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer

    Cervical

    Endometrial

CTSU G0258     Consent   HIPAA   Fast Facts    Protocol   

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

CTSU G0249    Consent    HIPAA  Fast Facts    Protocol   Treatment Calendar

Phase III Trial of Pelvic Radiation Therapy vs Vaginal Cuff Brachytherappy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer

       Uterine

CTSU G0261   Consent    HIPAA  Fast Facts   Protocol    

A Randomized Phase III Trial of Paclitaxel Plus Carboplatin vs Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary

CTSU G0238  Consent   HIPAA   Schema   Protocol  

A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

HEAD & NECK

CTSU E1305   Consent      HIPAA   Fast Facts   Protocol  (temporary partial closure-pre-menopausal women 1/25/12)

A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

RTOG R0920    Consent     HIPAA   Fast Facts   Protocol  

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

RTOG R1016   Consent    HIPAA    Protocol     Schema

Phase III Trial of Radiotherapy Plus Cetuximab vs Chemotherapy in HPV-Associated Oropharynx Cancer

LEUKEMIA

    Acute Myelogenous Leukemia

SWOG S0535    Consent   HIPAA  Protocol   (temporary closure)

Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously-untreated High-risk Acute Promyelocytic Leukemia

SWOG S0703      Consent   HIPAA  Protocol   (Good-risk group accrual closed)

A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia

SWOG S0919   Consent    HIPAA     Protocol   

Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)

CTSU E2906   Consent   HIPAA   Fast Facts   Protocol  

Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years)

Maintenance

     Myelodysplastic Syndrome

CTSU E2905   Consent    HIPAA  Fast Facts  Protocol  

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

      Lymphoblastic Leukemia

SWOG C10403   Consent     HIPAA      Protocol     (MCC treats adults only -- must be > 18 yrs)

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia

SWOG S0805   Consent     HIPAA  Schema  Protocol    (see protocol note regarding doxorubicin shortage)

Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell Transplant in Patients with Ph-Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL)

SWOG S0910   Consent   HIPAA   Protocol   Treatment Calendar

A Phase II Study of Epratuzumab in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Negative Precursor B-cell Acute Lymphoblastic Leukemia (ALL)

    Chronic Leukemia

SWOG C10404  Consent    HIPAA    Protocol  

A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

CTSU E1908    Consent   HIPAA  Schema  Protocol  

A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients using Alemtuzumab, and Rituximab

LUNG 

Non-Small Cell

Local

CTSU ACOSOG Z4099/RTOG 1021   Consent    HIPAA  Protocol  

A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

Adjuvant

CTSU E1505     Consent   HIPAA   Fast Facts     Protocol   Treatment Calendar Arm A  Arm B  AE Flowsheet  (temporary partial closure-pre-menopausal women 1/25/12)

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer

SWOG S0720  Consent    HIPAA  Fast Facts   Protocol    AE Flowsheet   Treatment Calendar Arm 1   Arm 2  (4/2011 temporary closure)

Phase II ERCC1 and RRM2-Based Adjuvant Therapy Trial in Patients with Stage I Non-small Cell Lung Cancer (NSCLC)

Advanced

SWOG S0819  Consent   HIPAA     Protocol  Treatment Calendar Arm 1a  Arm 1b  Arm 2a   Arm 2b  AE Flowsheet  Taxol shortage memo  (temporary partial closure-pre-menopausal women 1/25/12)

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

SWOG S0709  Consent   HIPAA  Fast Facts   Protocol    Treatment Calendar Arm 1   Arm 2

Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/Erlotinib or Erlotinib Alone in Advanced NSCLC Patients with Performance Status 2 Selected by Serum Proteomics

CTSU C30607   Consent    HIPAA   Fast Facts   Protocol  

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

CTSU C30801  Consent   HIPAA  Fast Facts   Protocol

A Randomized Phase III Double-blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer

CTSU E5508   Consent    HIPAA   Fast Facts  Protocol   (temporary partial closure-pre-menopausal women 1/25/12)

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Small Cell

SWOG S0802    Consent     HIPAA    Protocol    Treatment Calendar    AE Flowsheet  (partial closure- platinum refractory stratum)

A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)

CTSU C30610   Consent    HIPAA   Fast Facts     Protocol   

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

NCCTG N0923    Consent    HIPAA     Protocol 

A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum Containing Induction Regimens of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung

RTOG R0937        Consent    HIPAA    Protocol 

Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative  Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED_SCLC)

   Lung-Other

SWOG S0905   Consent    HIPAA    Protocol  

A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma

LYMPHOMA

    Hodgkin's

SWOG S0816   Consent    HIPAA   Fast Facts   Protocol 

A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkins Lymphoma using Early Interim FDG-PET Imaging

CTSU C50604   Consent     HIPAA   Schema   Protocol

Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

   Non-Hodgkin's

CTSU CALGB 50303    Consent   Consent Addendum   HIPAA    Fast Facts    Protocol

Randomized Study of R-CHOP versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated DeNovo Diffuse Large B-Cell Lymphomas

SWOG S0806  Consent   HIPAA    Protocol    (Phase II active)

A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma

SWOG S1001   Consent    HIPAA    Protocol  

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma

T-Cell

SWOG S1108   Consent  HIPAA   Protocol  

A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Mantle Cell

NCCTG N078D     Consent -1A     Consent -1B    HIPAA     Protocol  (call MCC for current status)

Phase I/II Trial of Tituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

 Melanoma     

NCCTG N0879  Consent   HIPAA    Protocol   (temporary closure 1/25/12)

A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma

CTSU E1609  Consent   HIPAA   Protocol   Treatment Calendar Arm A

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma

CTSU E2607   Consent    HIPAA  Protocol   Schema   (temporary closure 1/13/2012)

A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas

Myeloma

CTSU E3A06   Consent   HIPAA    Fast Facts   Protocol   (temporary closure 12/16/11 end of Ph II accrual)

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

CTSU E4A08  Consent   HIPAA    Protocol  

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation

Transplant

Sarcoma 

None

Other  

NCCTG N0871   Consent     HIPAA    Protocol  

A Phase II Study of Carboplatin, Paclitaxel and Everolimus in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary

RTOG R0631     Consent    HIPAA    Protocol  (Phase III open)

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

CTSU E4A08  Consent   HIPAA    Protocol  

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation

 

Return to the Top